INmune Bio Inc. (INMB) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero, and a member of our team will be happy to help you. Thank you. . . . . . ¶¶ Thank you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero, and a member of our team will be happy to help you. 🎵 🎵 ¦ ¦ ¦ © transcript Emily Beynon Please stand by. Your meeting is about to begin. Greetings and welcome to the ImmuneBio's 2025 Fourth Quarter and Year-End Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is now my pleasure to introduce Mr. Daniel Carlson, Head of Investor Relations of ImmuneBio, Daniel. Thank you, Chloe, and good afternoon, everyone. We thank you for joining us on the call for ImmuneBio's 2025 fourth quarter and year-end financial results. Presenting on today's call are David Moss, CEO and co-founder of ImmuneBio, Dr. Mark Lodell, Chief Scientific Officer and co-founder of ImmuneBio, Dr. C.J. Barnum, Head of Neuroscience, and Corey Elsperman, Indian Bios CFO. Before we begin, I remind everyone that except for statements of historical fact, the statements made by management and responses to question on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings, including our most rec...